Antineoplastics
1
Reactions 1517, p30 - 6 Sep 2014 Antineoplastics Rash and fatigue: case report A 53-year-old woman developed rash and fatigue while receiving erlotinib [Tarceva], trastuzumab [Herceptin], methotrexate and cyclophosphamide [Cytoxan]. The woman had been diagnosed with metastatic grade 3 invasive ductal carcinoma after presenting with signs of carcinoma of the right breast. She had initially responded well to chemotherapy, but her disease subsequently progressed. She received trastuzumab, methotrexate, cyclophosphamide, lapatinib and capecitabine; but genetic analysis of breast and skin tissue indicated that she had developed resistance to HER2-targeted therapy. Her regimen was altered; trastuzumab and metronomic therapy with methotrexate and cyclophosphamide was continued [dosages and routes not stated] and oral erlotinib 150mg once daily was introduced. She tolerated the combined therapy but developed fatigue and rash [duration of treatments to reaction onsets not stated, outcomes not stated]. The woman continued to receive the regimen and her disease responded; however, some time later, her condition later deteriorated and she was referred to hospice care. Author comment: "The patient tolerated the combined therapy with minimal fatigue and rash." Ali SM, et al. Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. Clinical Breast Cancer 14: e14-e16, No. 1, Feb 2014 - USA 803107607 1 Reactions 6 Sep 2014 No. 1517 0114-9954/14/1517-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1517, p30 - 6 Sep 2014
Antineoplastics
Rash and fatigue: case reportA 53-year-old woman developed rash and fatigue while
receiving erlotinib [Tarceva], trastuzumab [Herceptin],methotrexate and cyclophosphamide [Cytoxan].
The woman had been diagnosed with metastatic grade 3invasive ductal carcinoma after presenting with signs ofcarcinoma of the right breast. She had initially responded wellto chemotherapy, but her disease subsequently progressed.She received trastuzumab, methotrexate, cyclophosphamide,lapatinib and capecitabine; but genetic analysis of breast andskin tissue indicated that she had developed resistance toHER2-targeted therapy. Her regimen was altered; trastuzumaband metronomic therapy with methotrexate andcyclophosphamide was continued [dosages and routes notstated] and oral erlotinib 150mg once daily was introduced.She tolerated the combined therapy but developed fatigue andrash [duration of treatments to reaction onsets not stated,outcomes not stated].
The woman continued to receive the regimen and herdisease responded; however, some time later, her conditionlater deteriorated and she was referred to hospice care.
Author comment: "The patient tolerated the combinedtherapy with minimal fatigue and rash."Ali SM, et al. Antitumor response of an ERBB2 amplified inflammatory breastcarcinoma with EGFR mutation to the EGFR-TKI erlotinib. Clinical Breast Cancer14: e14-e16, No. 1, Feb 2014 - USA 803107607
1
Reactions 6 Sep 2014 No. 15170114-9954/14/1517-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved
